Similar articles

• Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting in July 2016 on chronic venous disease: An important first step.

  Lawrence PF. Lawrence PF. J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):301-302. doi: 10.1016/j.jvsv.2017.02.004. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 28411693 No abstract available.
• Product reimbursement and APCs: why all the fuss?

  Papatheofanis FJ. Papatheofanis FJ. IEEE Eng Med Biol Mag. 2002 Sep-Oct;21(5):19. doi: 10.1109/memb.2002.1044153. IEEE Eng Med Biol Mag. 2002. PMID: 12405053 No abstract available.
• Centers for Medicare & Medicaid Services' decision on drug-coated balloons: No additional reimbursement despite higher cost and highest levels of scientific evidence.

  Shishehbor MH, White CJ, Beckman JA, Misra S, Schneider PA, Lookstein RA, Kashyap VS, Clair D, Jones WS, Rosenfield K, Katzen BT, Jaff MR. Shishehbor MH, et al. Vasc Med. 2018 Dec;23(6):558-559. doi: 10.1177/1358863X18802969. Epub 2018 Sep 21. Vasc Med. 2018. PMID: 30238852 No abstract available.
• Managing the Economic Challenges in the Treatment of Heart Failure.

  Piña IL, Desai NR, Allen LA, Heidenreich P. Piña IL, et al. Prog Cardiovasc Dis. 2018 Nov-Dec;61(5-6):476-483. doi: 10.1016/j.pcad.2018.10.002. Epub 2018 Oct 25. Prog Cardiovasc Dis. 2018. PMID: 30565564 Review.
• The five things we all need to know about MACRA and alternative payment systems to compete and flourish.

  Dalsing MC. Dalsing MC. J Vasc Surg. 2018 Mar;67(3):970-973. doi: 10.1016/j.jvs.2017.09.012. Epub 2017 Nov 13. J Vasc Surg. 2018. PMID: 29141787 Review.